

# Daniel Rayson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3562970/publications.pdf>

Version: 2024-02-01

149  
papers

3,585  
citations

136940

32  
h-index

144002

57  
g-index

149  
all docs

149  
docs citations

149  
times ranked

5462  
citing authors

#	ARTICLE	IF	CITATIONS
1	Current and future landscape of targeted therapy in HER2-positive advanced breast cancer: redrawing the lines. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592110666.	3.2	16
2	HER2 testing in metastatic breast cancer – Is reflex ISH testing necessary on HER2 IHC-equivocal (2+) cases?. <i>Annals of Diagnostic Pathology</i> , 2022, 59, 151953.	1.3	0
3	Independent primary cutaneous and mammary apocrine carcinomas with neuroendocrine differentiation: Report of a case and literature review. <i>Journal of Cutaneous Pathology</i> , 2021, 48, 1397-1403.	1.3	6
4	Cardio-Oncology. <i>Journal of Clinical Oncology</i> , 2021, 39, 2962-2963.	1.6	0
5	Camouflage. <i>Journal of Clinical Oncology</i> , 2020, 38, 281-282.	1.6	1
6	Comparative performance of different methods for circulating tumor cell enrichment in metastatic breast cancer patients. <i>PLoS ONE</i> , 2020, 15, e0237308.	2.5	42
7	The association between breast density and HER2-positive breast cancer: A population-based case-control study.. <i>Journal of Clinical Oncology</i> , 2020, 38, e12556-e12556.	1.6	1
8	Title is missing!. , 2020, 15, e0237308.		0
9	Title is missing!. , 2020, 15, e0237308.		0
10	Title is missing!. , 2020, 15, e0237308.		0
11	Title is missing!. , 2020, 15, e0237308.		0
12	Title is missing!. , 2020, 15, e0237308.		0
13	Title is missing!. , 2020, 15, e0237308.		0
14	ACTH-Secreting Neuroendocrine Carcinoma of the Cecum: Case Report and Review of the Literature. <i>Clinical Colorectal Cancer</i> , 2019, 18, e163-e170.	2.3	5
15	Isolated Tumor Cells in Sentinel Lymph Nodes of Primary Invasive Breast Carcinoma: A Cohort Analysis. <i>Clinical Breast Cancer</i> , 2019, 19, 286-291.	2.4	2
16	Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). <i>Annals of Oncology</i> , 2019, 30, 766-773.	1.2	78
17	On Heartbreak in Oncology. <i>Current Oncology Reports</i> , 2019, 21, 7.	4.0	0
18	The role of scientific evidence in decisions to adopt complex innovations in cancer care settings: a multiple case study in Nova Scotia, Canada. <i>Implementation Science</i> , 2019, 14, 14.	6.9	17

#	ARTICLE	IF	CITATIONS
19	Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 443-449.	2.5	12
20	The effects of immunotherapy and novel therapies on medical oncology work load in a Canadian province.. <i>Journal of Clinical Oncology</i> , 2019, 37, 6532-6532.	1.6	0
21	Primary large cell neuroendocrine carcinoma of the skin: An under-recognized entity and a mimic of metastatic disease. <i>Journal of Cutaneous Pathology</i> , 2018, 45, 54-58.	1.3	6
22	Sweet Surrender. <i>Journal of Clinical Oncology</i> , 2018, 36, 3520-3521.	1.6	2
23	Cutaneous breast cancer metastasis mimicking flagellate erythema. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, AB92.	1.2	0
24	Report of metastatic ileal neuroendocrine tumor to the submandibular gland. <i>International Journal of Surgery Case Reports</i> , 2018, 53, 1-4.	0.6	1
25	Impact of Detection Method and Age on Survival Outcomes in Triple-Negative Breast Cancer: A Population-Based Cohort Analysis. <i>Clinical Breast Cancer</i> , 2018, 18, e955-e960.	2.4	5
26	Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal HR+/HER2- Advanced Breast Cancer. <i>Oncologist</i> , 2017, 22, 12-24.	3.7	14
27	To The Last Drop. <i>Journal of Clinical Oncology</i> , 2017, 35, 3083-3084.	1.6	4
28	Safety results of the Canadian Expanded Access Program (EAP) of palbociclib (PAL) plus letrozole (L) in postmenopausal patients (pts) with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) deemed appropriate candidates for first-line (1L) endocrine therapy (ET) with L.. <i>Journal of Clinical Oncology</i> , 2017, 35, e12534-e12534.	1.6	0
29	Decision-making by surgeons about referral for adjuvant therapy for patients with non-small-cell lung, breast or colorectal cancer: a qualitative study. <i>CMAJ Open</i> , 2016, 4, E7-E12.	2.4	5
30	Diagnosis and management of gastrointestinal neuroendocrine tumors: An evidence-based Canadian consensus. <i>Cancer Treatment Reviews</i> , 2016, 47, 32-45.	7.7	74
31	Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy. <i>Canadian Journal of Cardiology</i> , 2016, 32, 831-841.	1.7	190
32	Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 157, 109-116.	2.5	38
33	Cost-effectiveness of febrile neutropenia prevention with primary versus secondary G-CSF prophylaxis for adjuvant chemotherapy in breast cancer: a systematic review. <i>Breast Cancer Research and Treatment</i> , 2016, 159, 425-432.	2.5	11
34	White Knuckling. <i>Journal of Clinical Oncology</i> , 2016, 34, 1419-1420.	1.6	2
35	Pretreatment Serum Folate Levels and Toxicity/Efficacy in Colorectal Cancer Patients Treated With 5-Fluorouracil and Folinic Acid. <i>Clinical Colorectal Cancer</i> , 2016, 15, 369-376.e3.	2.3	7
36	Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes. <i>JAMA Oncology</i> , 2016, 2, 751.	7.1	243

#	ARTICLE	IF	CITATIONS
37	Is febrile neutropenia prophylaxis with granulocyte-colony-stimulating factors economically justified for adjuvant TC chemotherapy in breast cancer?. Supportive Care in Cancer, 2016, 24, 387-394.	2.2	8
38	Pre-treatment serum folate levels and toxicity in colorectal cancer patients treated with 5-fluorouracil and folinic acid.. Journal of Clinical Oncology, 2016, 34, 755-755.	1.6	0
39	Should ASCO re-examine the febrile neutropenia threshold for primary G-CSF prophylaxis in breast cancer?. Journal of Clinical Oncology, 2016, 34, e21671-e21671.	1.6	0
40	A Bag of Chips. Journal of Clinical Oncology, 2015, 33, 1214-1215.	1.6	0
41	Cost-Utility of Adjuvant Zoledronic Acid in Patients with Breast Cancer and Low Estrogen Levels. Current Oncology, 2015, 22, 246-253.	2.2	0
42	Investigations for patients with early-stage breast cancer: oversetting the stage. Cmaj, 2015, 187, 860-861.	2.0	3
43	Novel Agents and Associated Toxicities of Inhibitors of the PI3K/Akt/mTOR Pathway for the Treatment of Breast Cancer. Current Oncology, 2015, 22, 33-48.	2.2	95
44	Impact of the 2013 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 (HER2) testing of invasive breast carcinoma: a focus on tumours assessed as "equivocal" for HER2 gene amplification by fluorescence in situ hybridization. Histopathology, 2015, 67, 880-887.	2.9	57
45	Consensus Recommendations for the Diagnosis and Management of Pancreatic Neuroendocrine Tumors: Guidelines from a Canadian National Expert Group. Annals of Surgical Oncology, 2015, 22, 2685-2699.	1.5	76
46	Reflecting on Inpatient Palliative Chemotherapy "Is There Ever a "Right Place" at the "Right Time"?. Current Oncology, 2014, 21, 158-160.	2.2	0
47	Trastuzumab Beyond Progression for HER2 Positive Metastatic Breast Cancer: Progression-Free Survival on First-Line Therapy Predicts Overall Survival Impact. Breast Journal, 2014, 20, 408-413.	1.0	10
48	Incidence of febrile neutropenia in early stage breast cancer patients receiving adjuvant FEC-D treatment. Supportive Care in Cancer, 2014, 22, 3227-3234.	2.2	10
49	Terry Fox: Canadian Cancer Research Activist Whose "Marathon of Hope" Inspired Millions. Mayo Clinic Proceedings, 2014, 89, e75-e76.	3.0	3
50	Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study. Breast Cancer Research and Treatment, 2014, 146, 153-162.	2.5	43
51	Adjuvant denosumab for breast cancer: What efficacy in the D-CARE trial will translate into cost effectiveness?. Journal of Clinical Oncology, 2014, 32, 551-551.	1.6	1
52	Triple-negative breast cancer: A population-based description of clinical-pathologic correlates and survival outcomes as a function of age at diagnosis.. Journal of Clinical Oncology, 2014, 32, e12530-e12530.	1.6	0
53	Cost-effectiveness of aromatase inhibitors versus selective estrogen-receptor modulators for breast cancer prevention in postmenopausal women.. Journal of Clinical Oncology, 2014, 32, 1565-1565.	1.6	0
54	HER Story: The Next Chapter in HER-2-Directed Therapy for Advanced Breast Cancer. Oncologist, 2013, 18, 1153-1166.	3.7	16

#	ARTICLE	IF	CITATIONS
55	On Denying Denial. <i>Journal of Clinical Oncology</i> , 2013, 31, 4371-4372.	1.6	8
56	Is adjuvant trastuzumab a cost-effective therapy for HER-2/neu-positive T1bN0 breast cancer?. <i>Annals of Oncology</i> , 2013, 24, 1834-1840.	1.2	12
57	Cancer Narratives: Words beyond Diseaseâ€”A Call for Submissions. <i>Current Oncology</i> , 2013, 20, 84-84.	2.2	0
58	Endocrine Therapy for Postmenopausal Women with Hormone Receptorâ€”Positive her2â€”Negative Advanced Breast Cancer after Progression or Recurrence on Nonsteroidal Aromatase Inhibitor Therapy: A Canadian Consensus Statement. <i>Current Oncology</i> , 2013, 20, 48-61.	2.2	23
59	Human epidermal growth factor receptor 2 (HER2) suppression with the addition of lapatinib to trastuzumab in HER2-positive metastatic breast cancer (HALT: LPT112515).. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS664-TPS664.	1.6	1
60	Should adjuvant zoledronic acid be used in early-stage, endocrine-sensitive breast cancer?. <i>Journal of Clinical Oncology</i> , 2013, 31, e17564-e17564.	1.6	0
61	Abstract P6-07-07: Febrile neutropenia primary prophylaxis with granulocyte-colony stimulating factors (G-CSF) in breast cancer. , 2013, , .		0
62	Abstract P6-07-12: Should adjuvant zoledronic acid be used in early-stage, endocrine-sensitive breast cancer?. , 2013, , .		0
63	Chemotherapy Uptake and Wait Times in Early-Stage Non-Small-Cell Lung Cancer. <i>Current Oncology</i> , 2012, 19, 308-318.	2.2	4
64	Incidence of Febrile Neutropenia during Adjuvant Chemotherapy for Breast Cancer: A Prospective Study. <i>Current Oncology</i> , 2012, 19, 216-218.	2.2	8
65	Adherence to Clinical Practice Guidelines for Adjuvant Chemotherapy for Colorectal Cancer in a Canadian Province: A Population-Based Analysis. <i>Journal of Oncology Practice</i> , 2012, 8, 253-259.	2.5	37
66	Cardiac safety of adjuvant pegylated liposomal doxorubicin with concurrent trastuzumab: a randomized phase II trial. <i>Annals of Oncology</i> , 2012, 23, 1780-1788.	1.2	33
67	Parallel Lives Diverge. <i>Journal of Clinical Oncology</i> , 2012, 30, 2016-2018.	1.6	1
68	Primary G-CSF prophylaxis for adjuvant TC or FEC-D chemotherapy outside of clinical trial settings: a systematic review and meta-analysis. <i>Supportive Care in Cancer</i> , 2012, 20, 2523-2530.	2.2	47
69	How do surgeons decide to refer patients for adjuvant cancer treatment? Protocol for a qualitative study. <i>Implementation Science</i> , 2012, 7, 102.	6.9	2
70	Controlling angiogenesis in breast cancer: A systematic review of anti-angiogenic trials. <i>Cancer Treatment Reviews</i> , 2012, 38, 673-688.	7.7	97
71	313 A Pooled Analysis to Evaluate the Incidence of Proteinuria, Hypoalbuminemia, and Edema Secondary to MET and VEGFR Inhibition. <i>European Journal of Cancer</i> , 2012, 48, 96.	2.8	0
72	Compression garments versus compression bandaging in decongestive lymphatic therapy for breast cancer-related lymphedema: a randomized controlled trial. <i>Supportive Care in Cancer</i> , 2012, 20, 1031-1036.	2.2	57

#	ARTICLE	IF	CITATIONS
73	Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 1115-1123.	2.5	56
74	Routine Cardiac Evaluation in Patients With Early-Stage Breast Cancer Before Adjuvant Chemotherapy. <i>Clinical Breast Cancer</i> , 2012, 12, 4-9.	2.4	25
75	Improving Nodal Harvest in Colorectal Cancer: So What?. <i>Annals of Surgical Oncology</i> , 2012, 19, 1066-1073.	1.5	23
76	A phase II study of foretinib in triple-negative, recurrent/metastatic breast cancer: NCIC CTG trial IND.197 (NCT01147484).. <i>Journal of Clinical Oncology</i> , 2012, 30, 1036-1036.	1.6	3
77	HALT MBC: HER2 suppression with the addition of lapatinib to trastuzumab in HER2-positive metastatic breast cancer (LTP112515).. <i>Journal of Clinical Oncology</i> , 2012, 30, TPS658-TPS658.	1.6	0
78	Abstract OT1-1-07: Human epidermal growth factor receptor 2 (HER2) suppression with the addition of lapatinib to trastuzumab in HER2-positive metastatic breast cancer (LTP112515). , 2012, , .		0
79	P332 Population-based incidence of febrile neutropenia during adjuvant chemotherapy for breast cancer: A prospective study. <i>Breast</i> , 2011, 20, S80-S81.	2.2	2
80	Comparison of Clinical-Pathologic Characteristics and Outcomes of True Interval and Screen-Detected Invasive Breast Cancer Among Participants of a Canadian Breast Screening Program: A Nested Case-Control Study. <i>Clinical Breast Cancer</i> , 2011, 11, 27-32.	2.4	41
81	Immunohistochemical Expression and Prognostic Value of ER, PR and HER2/neu in Pancreatic and Small Intestinal Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2011, 93, 249-258.	2.5	31
82	Negotiations and Love Songs. <i>Journal of Clinical Oncology</i> , 2011, 29, 777-778.	1.6	1
83	Evaluating Survivorship Care Plans: Results of a Randomized, Clinical Trial of Patients With Breast Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 4755-4762.	1.6	298
84	Loss of Expression of DNA Mismatch Repair Proteins Is Rare in Pancreatic and Small Intestinal Neuroendocrine Tumors. <i>Archives of Pathology and Laboratory Medicine</i> , 2011, 135, 1539-1544.	2.5	31
85	Clinical practice guidelines (CPGs) for adjuvant chemotherapy (aCT) in colorectal cancer: A population-based analysis of adherence and non-receipt.. <i>Journal of Clinical Oncology</i> , 2011, 29, 6064-6064.	1.6	0
86	The potential economic impact of the 21-gene recurrence score–guided chemotherapy in a population-based cohort with node-negative and node-positive early-stage breast cancer.. <i>Journal of Clinical Oncology</i> , 2011, 29, e16520-e16520.	1.6	0
87	The potential economic impact of the 21-gene recurrence score: Guided chemotherapy in a population-based cohort with node-negative and node-positive early-stage breast cancer.. <i>Journal of Clinical Oncology</i> , 2011, 29, 201-201.	1.6	1
88	P5-20-04: Is Primary Prophylaxis with G-CSF Indicated for Adjuvant TC or FEC-D Chemotherapy? A Systematic Review and Meta-Analyses.. , 2011, , .		0
89	Quantifying limitations in chemotherapy data in administrative health databases: implications for measuring the quality of colorectal cancer care. <i>Healthcare Policy</i> , 2011, 7, 32-40.	0.6	3
90	Flat Epithelial Atypia on Breast Needle Core Biopsy: A Retrospective Study with Clinical-Pathological Correlation. <i>Breast Journal</i> , 2010, 16, no-no.	1.0	25

#	ARTICLE	IF	CITATIONS
91	Optimizing the Management of her2-Positive Early Breast Cancer: The Clinical Reality. Current Oncology, 2010, 17, 20-33.	2.2	25
92	Inter-Institutional Pathology Consultations for Breast Cancer: Impact on Clinical Oncology Therapy Recommendations. Current Oncology, 2010, 17, 25-32.	2.2	21
93	Accrual Strategies for Cancer Genetics Research: Blurred Boundaries. Journal of Clinical Oncology, 2010, 28, e308-e308.	1.6	2
94	Adjuvant endocrine monotherapy with tamoxifen or aromatase inhibitors for postmenopausal women with breast cancer: What is the economic impact of CYP 2D6 testing?. Journal of Clinical Oncology, 2010, 28, 6010-6010.	1.6	1
95	Changes in chemotherapy uptake and wait times in early-stage non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2010, 28, 6049-6049.	1.6	0
96	Baseline MUGA scans for patients with early-stage breast cancer receiving adjuvant chemotherapy.. Journal of Clinical Oncology, 2010, 28, 6087-6087.	1.6	0
97	Abstract P5-11-15: Modeling for Response Predictive Factors in Adjuvant Endocrine Therapy: Impact on Preferential Benefits of Tamoxifen and Aromatase Inhibitors. , 2010, , .		0
98	Management of Skin Rash during egfr-Targeted Monoclonal Antibody Treatment for Gastrointestinal Malignancies: Canadian Recommendations. Current Oncology, 2009, 16, 16-26.	2.2	120
99	The Role of her2-Targeted Therapies in Women with her2-Overexpressing Metastatic Breast Cancer. Current Oncology, 2009, 16, 25-35.	2.2	15
100	The Role of Neoadjuvant her2-Targeted Therapies in her2-Overexpressing Breast Cancers. Current Oncology, 2009, 16, 48-57.	2.2	10
101	Phase II Multicenter Trial of Anthracycline Rechallenge With Pegylated Liposomal Doxorubicin Plus Cyclophosphamide for First-Line Therapy of Metastatic Breast Cancer Previously Treated With Adjuvant Anthracyclines. Journal of Clinical Oncology, 2009, 27, 5906-5910.	1.6	33
102	Survivin and COX-2 expression in male breast carcinoma. Breast, 2009, 18, 228-232.	2.2	13
103	Predicting benefit from fulvestrant in pretreated metastatic breast cancer patients. Breast Cancer Research and Treatment, 2009, 118, 377-383.	2.5	8
104	Identifying mental health services in clinical genetic settings. Clinical Genetics, 2009, 76, 326-331.	2.0	4
105	The Cost-Utility of Sequential Adjuvant Trastuzumab in Women with Her2/Neu-Positive Breast Cancer: An Analysis Based On Updated Results from the HERA Trial. Value in Health, 2009, 12, 641-648.	0.3	31
106	Developing a prediction model for benefit from fulvestrant in heavily pretreated metastatic breast cancer patients. Breast Cancer Research, 2009, 11, .	5.0	0
107	Adjuvant chemotherapy in breast cancer: is TC a cost-effective regimen compared to AC?.. , 2009, , .		0
108	Adjuvant chemotherapy for breast cancer: a cost-utility analysis of FEC-D vs. FEC 100. Breast Cancer Research and Treatment, 2008, 111, 261-267.	2.5	25

#	ARTICLE	IF	CITATIONS
109	The development of a predictive model to estimate cardiotoxic risk for patients with metastatic breast cancer receiving anthracyclines. <i>Breast Cancer Research and Treatment</i> , 2008, 107, 443-450.	2.5	62
110	Pegylated liposomal doxorubicin-associated hand-foot syndrome: Recommendations of an international panel of experts. <i>European Journal of Cancer</i> , 2008, 44, 781-790.	2.8	122
111	Metastatic breast cancer: The role of pegylated liposomal doxorubicin after conventional anthracyclines. <i>Cancer Treatment Reviews</i> , 2008, 34, 391-406.	7.7	65
112	Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies. <i>Annals of Oncology</i> , 2008, 19, 1530-1539.	1.2	82
113	Waiting Times in Early-Stage Non-small Cell Lung Cancer (NSCLC). <i>Journal of Thoracic Oncology</i> , 2008, 3, 865-870.	1.1	35
114	Identifying Patients at High Risk for Neutropenic Complications During Chemotherapy for Metastatic Breast Cancer With Doxorubicin or Pegylated Liposomal Doxorubicin. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2008, 31, 369-374.	1.3	29
115	The Cost Burden of Trastuzumab and Bevacizumab Therapy for Solid Tumours in Canada. <i>Current Oncology</i> , 2008, 15, 136-142.	2.2	34
116	Does Her2/neu status affect adjuvant chemotherapy utilization? A population based analysis. <i>Journal of Clinical Oncology</i> , 2008, 26, 11549-11549.	1.6	1
117	Accounting for improved outcomes in budget impact analyses: Adjuvant trastuzumab in HER2/neu-positive breast cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 6573-6573.	1.6	2
118	Clinical-pathologic characteristics of true interval and screen-detected breast cancer among participants in a Canadian breast screening program: A nested case-control study. <i>Journal of Clinical Oncology</i> , 2008, 26, 638-638.	1.6	0
119	Wait times for breast cancer care. <i>British Journal of Cancer</i> , 2007, 96, 162-168.	6.4	33
120	Modeling for cost-effective-adjuvant aromatase inhibitor strategies for postmenopausal women with breast cancer. <i>Annals of Oncology</i> , 2007, 18, 293-298.	1.2	13
121	Comparison of elapsed times from breast cancer detection to first adjuvant therapy in Nova Scotia in 1999/2000 and 2003/04. <i>Cmaj</i> , 2007, 176, 327-332.	2.0	24
122	Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women with breast cancer: Upfront anastrozole, sequential tamoxifen-exemestane and extended tamoxifen-letrozole. <i>Breast</i> , 2007, 16, 252-261.	2.2	18
123	P142 Rechallenge of patients previously treated with adjuvant anthracyclines using pegylated liposomal doxorubicin (PLD) with cyclophosphamide (C) as first-line chemotherapy for metastatic breast cancer (MBC). <i>Breast</i> , 2007, 16, S54.	2.2	1
124	Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women: sequential tamoxifen-exemestane and upfront anastrozole. <i>Breast Cancer Research and Treatment</i> , 2007, 101, 325-333.	2.5	26
125	The decision-making experience among women diagnosed with stage I and II breast cancer. <i>Breast Cancer Research and Treatment</i> , 2007, 102, 51-59.	2.5	23
126	Clinical and pathological correlations in male breast cancer: intratumoral aromatase expression via tissue microarray. <i>Breast Cancer Research and Treatment</i> , 2007, 105, 169-175.	2.5	20



#	ARTICLE	IF	CITATIONS
127	Transitions to palliation: Two solitudes or inevitable integration?. <i>Current Oncology Reports</i> , 2007, 9, 285-289.	4.0	11
128	Metaplastic breast carcinoma: clinical and pathologic characteristics and HER2/neu expression. <i>Breast Cancer Research and Treatment</i> , 2005, 91, 173-178.	2.5	100
129	Witness. <i>Journal of Clinical Oncology</i> , 2005, 23, 2429-2430.	1.6	1
130	Patterns of trastuzumab use and cost in a single Canadian cancer institute. <i>Journal of Clinical Oncology</i> , 2005, 23, 6070-6070.	1.6	3
131	Economic evaluation of adjuvant hormonal options in postmenopausal women with breast cancer: Tamoxifen vs tamoxifen then exemestane vs anastrozole. <i>Journal of Clinical Oncology</i> , 2005, 23, 6040-6040.	1.6	0
132	Elapsed time from breast cancer detection to first adjuvant therapy in a Canadian province, 1999-2000. <i>Cmaj</i> , 2004, 170, 957-961.	2.0	22
133	Exercise and Cancer: No Pain, Some Gain?. <i>Journal of Clinical Oncology</i> , 2003, 21, 1651-1652.	1.6	6
134	Hereditary Breast Cancer: Shared Communication and Care. <i>Journal of Clinical Oncology</i> , 2003, 21, 4660-4660.	1.6	0
135	Sweet Time Unafflicted. <i>Journal of Clinical Oncology</i> , 2003, 21, 46s-48.	1.6	0
136	Adjuvant Chemotherapy For Women With Young Children: Our Patients as Parents. <i>Journal of Clinical Oncology</i> , 2003, 21, 114s-116.	1.6	0
137	Sweet Time Unafflicted. <i>Journal of Clinical Oncology</i> , 2002, 20, 4603-4604.	1.6	4
138	Adjuvant Chemotherapy For Women With Young Children: Our Patients as Parents. <i>Journal of Clinical Oncology</i> , 2001, 19, 279-281.	1.6	11
139	Outcome after ovarian/adnexal metastectomy in metastatic colorectal carcinoma. <i>Journal of Surgical Oncology</i> , 2000, 75, 186-192.	1.7	60
140	Metaplastic breast cancer: Prognosis and response to systemic therapy. <i>Annals of Oncology</i> , 1999, 10, 413-419.	1.2	196
141	Lisa's Stories. <i>JAMA - Journal of the American Medical Association</i> , 1999, 282, 1605.	7.4	3
142	Angiogenesis as a target for breast cancer therapy. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 1999, 4, 415-423.	2.7	10
143	The concept of Tenju-gann, or "natural-end cancer?". , 1999, 85, 1197-1198.		0
144	Scleromyxedema: A Complete Response to Prednisone. <i>Mayo Clinic Proceedings</i> , 1999, 74, 481-484.	3.0	27

#	ARTICLE	IF	CITATIONS
145	Sarcoidosis and testicular carcinoma. <i>Cancer</i> , 1998, 83, 337-343.	4.1	89
146	Molecular markers in male breast carcinoma. <i>Cancer</i> , 1998, 83, 1947-1955.	4.1	145
147	Thrombosis of the Internal Jugular Vein: A Rare Manifestation of the Hypercoagulability of Malignancy. <i>Cancer Investigation</i> , 1998, 16, 319-321.	1.3	4
148	Regression of metastatic carcinoid tumor after valvular surgery for carcinoid heart disease. <i>Cancer</i> , 1997, 79, 605-611.	4.1	19
149	27-Year-Old Woman With Pancytopenia. <i>Mayo Clinic Proceedings</i> , 1995, 70, 185-188.	3.0	2